Moderna gets $590M from US government

Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
HHS gives Moderna $590M to 'accelerate' bird flu vaccine trials
The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains with pandemic potential.
Moderna Gets $590 Million to Develop Bird Flu Vaccine
The government is working to head off human bird flu infections. The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Moderna Nabs Another $590M from HHS for mRNA-Based Bird Flu Vaccines
The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready before bird flu strains currently circulating in the wild and on farms can potentially cause human outbreaks.
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023.
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump
Shares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a $590 million award from the U.S. Health and Human Services Department to accelerate its bird flu vaccine development.
Moderna secures $590M in government funding to develop bird flu vaccine
The U.S. government has awarded Moderna $590 million to help speed up the development of a bird flu vaccine. President Trump ends marathon inauguration day at three inaugural balls José Andrés Says This Is the Best Substitute for Salt Macron announces plan for mobilization of volunteers Real-life “Yellowstone” cowboy went from sleeping in a tent to a building a TV empire New Bears coach Ben Johnson eyeing two former NFL head coaches for his staff in Chicago,
Where Will Moderna Be in 3 Years?
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
From Covid to Norovirus: Moderna’s mRNA Tech Takes on Stomach Flu
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Is Moderna Stock a Buy?
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
3-Stock Lunch: 3M, Moderna, & T-Mobile
Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.
Why Is Moderna Stock Trading Higher On Tuesday?
Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
These Stocks Are Moving the Most Today: Tesla, Apple, 3M, D.R. Horton, Charles Schwab, Moderna, Walgreens, and More
Tesla falls on Trump’s plans to roll back EV production targets, Apple gets a downgrade, and 3M and Charles Schwab score ...